🔗 Share this article

While the United States undertakes historic revisions to its immunization recommendations, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has concentrated on alleged deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Schedule

Health officials planned to reveal major revisions to the pediatric immunization program earlier this month, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with many the world with little proof for benefit. This reveal has been postponed until the coming year.

Instead of the director of the vaccine center, Høeg is listed to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to run the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing some pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a society with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Expertise

The appointee has little discernible experience in medication creation, approval processes or leadership, which has been customary for past heads of the biologics center. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a large organization. She is not an expert in drug approvals.”

Previous commissioners of the center would “understand laws and regulations and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who led the center have had.”

This division has an vast portfolio at the FDA, she emphasized.

“The public just focuses on the novel medication approvals, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and all of those must be managed,” Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major leadership element to the job, which manages over 5,000 employees. “It is a massive management job, if you do it right,” Woodcock said.

Response and Controversial Programs

When asked about inquiries about Høeg’s qualifications and whether this selection represents increased cooperation among regulatory chiefs on immunizations, a representative stated that the “questions are based on inaccurate presumptions”.

“Her experience aligns with the duties of her job,” the representative said, citing the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed one-day drug-approval program that reportedly worried her former heads. “By what process are these medications being chosen for this fast-track system? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he said, “the agency seems to be moving towards laxer rules of most medications, except for immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, past, Howard observe. She released a research paper using unverified volunteer-provided data to assess the rate of myocarditis after COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new government featured revising rules for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from getting Covid vaccinations.

“She is an complete dogmatist who commences with her beliefs and tailors the evidence to fit the science in a very misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|